Background: Left ventricular hypertrophy (LVH) is an independent predictor of fatal and non-fatal cardiovascular events in hypertensive patients. Current guidelines for the management of hypertension are based on cardiovascular risk stratification. This study evaluated the possibility that an inexpensive, simple random, single-void urinary protein-to-creatinine ratio (UPCR) would be associated to left ventricular (LV) mass in a black African setting, and therefore direct appropriate management of these patients. Methods: We measured echocardiographic LV mass and a random spot UPCR in 34 untreated newly diagnosed hypertensive patients attending the cardiology consultation unit at the Yaoundé General Hospital. LV mass was indexed to height (in m2.7) to obtain the LV mass index (LVMI). A regression model was used to verify the independent association between UPCR and LVMI. Results: The mean age of our patients was 52.65 years, and the mean systolic and diastolic blood pressures were 152.44 and 92.84 mm Hg, respectively. The prevalence of LVH was 41.2%. UPCR was higher in patients with LVH compared to those without (p = 0.043). There was a significant correlation between UPCR and LVMI (r = 0.581, p < 0.001). In the multiple linear regression model, UPCR was associated with LVMI independent of systolic blood pressure (p < 0.001). Conclusion: Random spot UPCR is associated with an increased LV mass and may be very useful in screening and guiding appropriate management of high-risk untreated hypertensive patients.

Keywords:
Proteinuria, Left ventricular hypertrophy, Hypertension
1.
Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-1566.
2.
Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M: Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 2006;332:1426-1431.
3.
Dell'omo G, Giorgi D, Di Bello V, Mariani M, Pedrinelli R: Blood pressure independent association of microalbuminuria and left ventricular hypertrophy in hypertensive men. J Intern Med 2003;254:76-84.
4.
McQuarie EP, Rajan K, Patrick BM, Christian D, John C: Association between proteinuria and left ventricular mass index: a cardiac MRI study in patients with chronic kidney disease. Nephrol Dial Transplant 2011;26:933-938.
5.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2571.
6.
Palatini P, Graniero GR, Mormino P, Mattarei M, Sanzuol F, Cignacco GB, et al: Prevalence and clinical correlates of microalbuminuria in stage 1 hypertension. Am J Hypertens 1996;9:334-341.
7.
Redon J, Gomez-Sanchez MA, Baldo E, Casal MC, Fernandez ML, Miralles A, et al: Micro-albuminuria is correlated with left ventricular hypertrophy in male hypertensive patients. J Hypertens 1991;9:S148-S149.
8.
Shirafkan A, Motahari M, Mojerlou M, Rezghi Z, Behnampour N, Gholamrezanezhad A: Association between left ventricular hypertrophy with retinopathy and renal dysfunction in patients with essential hypertension. Singapore Med J 2009;50:1177-1183.
9.
Andrikou E, Costas T, Kyriakos D, Dimitrios F, Vagelis C, Charalampos G, et al: Parallel deterioration of albuminuria, arterial stiffness and left ventricular mass in essential hypertension: integrating target organ damage. Nephron Clin Pract 2011;119:c27-c34.
10.
Saitoh M, Matsuo K, Nomoto S, Kondoh T, Yanagawa T, Katoh Y, et al: Relationship between left ventricular hypertrophy and renal and retinal damage in untreated patients with essential hypertension. Intern Med 1998;37:576-580.
11.
Post WS, Blumenthal RS, Weiss JL, Levine DM, Thiemann DR, Gerstenblith G, et al: Spot urinary albumin-creatinine ratio predicts left ventricular hypertrophy in young hypertensive African-American men. Am J Hypertens 2000;13:1168-1172.
12.
Olusegun B, George O, Timothy O, Abo O, Ahmed J: Electrocardiographic correlates of microalbuminuria in adult Nigerians with essential hypertension. Cardiol J 2010;17:245-249.
13.
Rayner B, Becker P: The prevalence of microalbuminuria and ECG left ventricular hypertrophy in hypertensive patients in private practices in South Africa. Cardiovasc J S Afr 2006;17:245-249.
14.
Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-2158.
15.
Devereux RB, Alonso DR, Lutas EM, Gottlieb JG, Campo E, Sachs I, Reichek N: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-458.
16.
Quynh AT, Michael T, Amir AM, Fabian B, Ian SR, Ron B, et al: Relation of left ventricular mass and concentric remodeling to extent of coronary artery disease by computed tomography in patients without left ventricular hypertrophy: ROMICAT study. J Hypertens 2009;27:2472-2482.
17.
Isa MS, Bala GS, Oyati AI, Danbauchi SS: Patterns of left ventricular hypertrophy and geometry in newly diagnosed hypertensive adults in Northern Nigerians. Journal of Diabetes and Endocrinology 2010;1:1-5.
18.
Wachtell K, Olsen MH, Dahlof B, Devereux RB, Ljeldsen SE, Nieminen MS, et al: Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens 2002;20:405-412.
19.
Comper WD, Hilliard LM, Nikolic-Paterson DJ, Russo LM: Disease-dependent mechanisms of albuminuria. Am J Physiol Renal Physiol 2008;295:F1589-F1600.
20.
Dieplinger B, Mueller T, Kollerits B, Struck J, Ritz E, et al: Pro-A-type natriuretic peptide and pro-adrenomedullin predict progression of chronic kidney disease: the MMKD Study. Kidney Int 2009;75:408-414.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.